Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Immuno-oncology Therapies
26 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
Immuno-oncology
Activating the Immune System to Treat Cancer
PAO-01-22-R250-06
Cell Therapy
Economically Viable, Same-Day Autologous Cell Therapies
PAO-01-21-CL-06
M&A
Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.
PR-M01-20-NI-006
Immunotherapy
NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Combination Immunotherapy in Triple Negative Breast Cancer
PR-M12-19-NI-022
Immunotherapy
Collaborating for Immunotherapy Development
PAP-Q1-2019-NI-007
Immuno-oncology
Sanofi and Regeneron Immuno-oncology Collaboration Ending
PAO-M01-19-NI-012
Immuno-Oncology
FIMECS, Inc. Concludes Licensing Agreement with Takeda to Develop Novel Immuno-Oncology Therapies
PR-M04-18-NI-44
Immuno-oncology
Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
PR-M04-18-NI-40
Immuno-Oncology
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership
PR-M04-18-NI-030
Immuno-Oncology
European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
PR-M01-18-NI-082
Acquisition
Charles River Laboratories Continues to Grow Through Acquisition
PAO-M01-18-NI-035
Drug Development
Potenza Therapeutics Unveils Pipeline of Immuno-Oncology Programs
PR-M01-18-NI-024
Business
Cue Biopharma Announces Closing of Initial Public Offering
PR-M01-18-NI-003
Immuno-Oncology Therapies
ARMO BioSciences Files Registration Statement for Proposed Initial Public Offering
PR-M01-18-NI-001
Drug Development
Memory T Cells Fit to be Cross Trained
PAO-M12-17-NI-027
Oncology
Altering White Blood Cells to Kill Cancer
PAO-M12-17-NI-026
Innovation
Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment
PR-M12-17-NI-015
Immuno-oncology
Genentech and Biothera to Assess Combination Cancer Therapy
PAO-M12-17-NI-010
Immuno-oncology
Immuno-oncology Approach Based on Electronic Circuitry
PAO-M11-17-NI-008
Oncology
Bristol-Myers Squibb Will Acquire IFM Therapeutics’ Innate Immune System Stimulators
PAO-M08-17-NI-015
Drug Development
New Partnership Targets Colorectal Cancer with Combination Therapy, Including Avelumab
PAO-M06-17-NI-020
Clinical Trials
Checkmate Pharmaceuticals Receives Series B Funding for CMP-001
PAO-M06-17-NI-013
Immuno-Oncology
Bristol-Meyers Squibb, Array BioPharma Enter Strategic Collaboration
PAO-M05-17-NI-036
Combinational Immunotherapies: The Bright Future of Cancer Treatment
MCP-M04-17-NI-001
1
2
»
.svg)
